What is the appropriate losartan dose conversion for a patient currently taking benazepril?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Benazepril to Losartan Dose Conversion

When converting from benazepril to losartan, use a target dose of losartan 100 mg once daily if the patient was on benazepril 40 mg daily, or losartan 50 mg once daily if the patient was on benazepril 20 mg daily (50% of target dose). 1

Conversion Framework

The 2020 ACC/AHA guidelines provide clear target dosing for both ACE inhibitors and ARBs in heart failure with reduced ejection fraction, which serves as the framework for conversion 1:

Target Doses from Guidelines

Benazepril:

  • Target dose: 40 mg once daily
  • 50% of target: 20 mg once daily

Losartan:

  • Target dose: 100 mg once daily (per FDA labeling; ACC/AHA recommends 150 mg but FDA max is 100 mg)
  • 50% of target: 50 mg once daily

Practical Conversion Strategy

If patient is on benazepril 40 mg daily (target dose):

  • Switch to losartan 100 mg once daily
  • This represents equivalent target dosing for renin-angiotensin system inhibition

If patient is on benazepril 20 mg daily (50% of target):

  • Switch to losartan 50 mg once daily
  • Maintains equivalent proportional dosing

If patient is on benazepril 10 mg daily (25% of target):

  • Switch to losartan 25-50 mg once daily
  • Plan to uptitrate to at least 50 mg (50% of target) within 2 weeks if tolerated

Important Clinical Considerations

Dose-Response Evidence

The HEAAL trial demonstrated that losartan 150 mg daily was superior to 50 mg daily, with a 10% relative risk reduction in death or heart failure hospitalization 2, 3, 2. This underscores the importance of achieving higher doses when tolerated. Similarly, the ROAD study showed that uptitration of losartan to optimal antiproteinuric doses (median 100 mg, range 50-200 mg) resulted in 53% risk reduction for renal endpoints compared to conventional 50 mg dosing 4.

Titration Timeline

After conversion, adjust doses no more frequently than every 2 weeks to target doses or maximally tolerated doses 1. This allows adequate time to assess blood pressure response and monitor for adverse effects like hyperkalemia or renal dysfunction.

Monitoring Requirements

  • Check blood pressure, serum potassium, and creatinine within 1-2 weeks after conversion
  • Watch for symptomatic hypotension, particularly if patient is volume depleted
  • Losartan produces similar rates of hyperkalemia and renal dysfunction as ACE inhibitors 5, 6

Key Differences Between Agents

Cough: Losartan causes significantly less cough than benazepril (8-fold reduction in CORD trials) 7. This is the most common reason for switching from an ACE inhibitor to an ARB.

Angioedema: While rare with losartan, cases have occurred in patients who previously had angioedema with ACE inhibitors 5, 6. Exercise extreme caution and counsel patients on warning signs.

Efficacy equivalence: Multiple studies show comparable blood pressure reduction and metabolic effects between benazepril and losartan 7, 8, 9. The VALIANT trial demonstrated valsartan was non-inferior to captopril, supporting ARB use as an alternative to ACE inhibitors 2, 3.

Special Populations

Renal impairment: No dose adjustment needed unless patient is volume depleted 10, 11

Hepatic impairment: Start losartan at 25 mg daily in mild-to-moderate hepatic dysfunction 11

Black patients: The LIFE study showed Black patients had better outcomes with atenolol than losartan for cardiovascular endpoints, though blood pressure reduction was similar 11. Consider this when converting in Black patients with left ventricular hypertrophy.

Common Pitfall

Do not assume 1:1 mg equivalence between benazepril and losartan. The conversion is based on achieving equivalent target doses proven effective in clinical trials, not on milligram-to-milligram pharmacologic potency. A patient on benazepril 10 mg should not simply receive losartan 10 mg—this would be a subtherapeutic dose.

References

Related Questions

Should I increase the patient's losartan dose to 50 mg daily given a 3‑lb weight gain from 128 lb to 131 lb?
What is the appropriate next dose of losartan potassium after initiating 50 mg once daily?
What is the appropriate conversion from losartan 100 mg daily to benazepril for hypertension management?
Can I switch a 65-year-old male patient with uncontrolled hypertension and diabetes from ramipril (Angiotensin-Converting Enzyme Inhibitor) 5mg to losartan (Angiotensin II Receptor Antagonist) 50mg?
Can losartan be taken as needed (PRN) rather than daily?
In a 20-year-old patient with anterior uveitis, significant vision changes, and an elevated thyroid‑stimulating hormone (TSH) level of 7.2 mIU/L, does the high TSH complicate the treatment of the anterior uveitis?
For a patient with anterior uveitis who refuses oral prednisone due to concerns about weight gain, diabetes, and hypertension, and who has an elevated thyroid‑stimulating hormone (TSH) of 7.2 mIU/L, can topical prednisolone acetate 1% be used safely as first‑line therapy, and does the high TSH affect the treatment plan?
Why am I still experiencing cognitive cloudiness 16 days after discontinuing lurasidone (Latuda) and after starting extended‑release mixed amphetamine salts (Adderall XR) 10 mg, and when can I expect my mental clarity to return to normal?
What is the recommended treatment for Staphylococcus aureus peritoneal dialysis-associated peritonitis?
What is the innervation of cerebral vessels involved in the neurogenic regulation of cerebral blood flow?
What is the appropriate treatment for a red, itchy, scaly lesion on the right calf?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.